GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (FRA:UNC) » Definitions » Ending Cash Position

UCB (FRA:UNC) Ending Cash Position : €428 Mil (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is UCB Ending Cash Position?

UCB's Ending Cash Position for the quarter that ended in Jun. 2024 was €428 Mil.

UCB's quarterly Ending Cash Position increased from Jun. 2023 (€456 Mil) to Dec. 2023 (€861 Mil) but then declined from Dec. 2023 (€861 Mil) to Jun. 2024 (€428 Mil).

UCB's annual Ending Cash Position declined from Dec. 2021 (€1,244 Mil) to Dec. 2022 (€859 Mil) but then increased from Dec. 2022 (€859 Mil) to Dec. 2023 (€861 Mil).

UCB Ending Cash Position Historical Data

The historical data trend for UCB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Ending Cash Position Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,288.00 1,303.00 1,244.00 859.00 861.00

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 471.00 859.00 456.00 861.00 428.00

UCB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

UCB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=859+2
=861

UCB's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=861+-433
=428

UCB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of UCB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (FRA:UNC) » Definitions » Ending Cash Position
Comparable Companies
XBRU:ARGX XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX REGN ASX:CSL XKRX:207940 ALNY XKRX:068270 BNTX BGNE MRNA SMMT UTHR OCSE:GMAB XKRX:196170
Traded in Other Exchanges
UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UCB:Belgium UCB:Austria
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
Website
https://www.ucb.com
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB Headlines

No Headlines